Adverse Effects of HMG CoA Reductase Inhibitor and Garlic on Renal Function in Patients with Diabetic Dyslipidemia

被引:0
作者
Siddiqui, Naveed Ali [1 ]
Ishaque, Imran [2 ]
Rahat, Yousra [3 ]
Akhtar, Naheed [4 ]
Tehreem, Umaya [3 ]
Javed, Rafia [3 ]
Ali, Rayyan [3 ]
机构
[1] United Med & Dent Coll, Dept Biochem, Karachi, Pakistan
[2] United Med & Dent Coll, Dept Anat, Karachi, Pakistan
[3] United Med & Dent Coll, Karachi, Pakistan
[4] Karachi Inst Med Sceinces, Dept Anat, Karachi, Pakistan
来源
ANNALS ABBASI SHAHEED HOSPITAL & KARACHI MEDICAL & DENTAL COLLEGE | 2021年 / 26卷 / 02期
关键词
Urea; Creatinine; Diabetic dyslipidemia; HMG-CoA reductase inhibitor; Coronary heart disease; CARDIOVASCULAR-DISEASE; FAILURE SECONDARY; LIPID PROFILE; RHABDOMYOLYSIS; SIMVASTATIN;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: To analyze the adverse effects of HMG CoA reductase inhibitor (statin) and garlic (Allium sativum) on renal function in diabetic dyslipidemic patients. Methods: This clinical trial was conducted at Surgeon Munawar Memorial Hospital, Karachi from 1st March 2019 to 30th August 2019. Total of 60 patients of 30-70 years of age with abnormal lipid profile were enrolled for this study after a written consent. The study was conducted to assess the side effects of statin (20 mg/day) and garlic (300 mg/day) in diabetic dyslipidemia patients. The study period consisted of six months. Blood pressure, body weight and height of subjects were assessed. The patient answered the questionnaire on health complaints, smoking, social role, drug usage, family history and dietary pattern. The initial inclusion criteria of the patient were 1) Age between 30-70 years old of either sex, 2) Patients with diabetic dyslipidemia. The exclusion criteria were 1) Pregnancy or lactation, 2) Patients with liver diseases, 3) Patients with renal diseases. Detailed medical history and physical examination of all patients were carried out. Results: This study included 60 patients with an abnormal lipid profile of age 30-70 years. International statin product (20 mg/day) and local garlic product (300 mg/day) for 08 weeks were used for oral administration in patients. Urea and creatinine levels in the serum of diabetic dyslipidemic patients were measured before and after treatment with an international statin (20 mg/day) and a local garlic product (300 mg/day). Conclusion: According to the findings of this study, statins increase the serum level of urea and creatinine while has no effect on urea and creatinine serum level.
引用
收藏
页码:71 / 75
页数:5
相关论文
共 50 条
  • [31] Morelloflavone from Garcinia dulcis as a Novel Biflavonoid Inhibitor of HMG-CoA Reductase
    Tuansulong, Ku-aida
    Hutadilok-Towatana, Nongporn
    Mahabusarakam, Wilawan
    Pinkaew, Decha
    Fujise, Ken
    PHYTOTHERAPY RESEARCH, 2011, 25 (03) : 424 - 428
  • [32] Simvastatin: In Vitro Metabolic Profiling of a Potent Competitive HMG-CoA Reductase Inhibitor
    Yin, Wencui
    Alwabli, Reem I.
    Attwa, Mohamed W.
    Rahman, A. F. M. Motiur
    Kadi, Adnan A.
    SEPARATIONS, 2022, 9 (12)
  • [33] EFFICACY AND SHORT-TERM EFFECTS OF PRAVASTATIN, A POTENT INHIBITOR OF HMG-COA REDUCTASE, ON HYPERCHOLESTEROLEMIA IN CLIMACTERIC WOMEN
    USHIROYAMA, T
    IKEDA, A
    UEKI, M
    SUGIMOTO, O
    JOURNAL OF MEDICINE, 1994, 25 (05) : 319 - 331
  • [34] The Effects of Combined Treatment with an HMG-CoA Reductase Inhibitor and PPARγ Agonist on the Activation of Rat Pancreatic Stellate Cells
    Lee, Beom Jae
    Lee, Hong Sik
    Kim, Chang Duck
    Jung, Sung Woo
    Seo, Yeon Seok
    Kim, Yong Sik
    Jeen, Yoon Tae
    Chun, Hoon Jai
    Um, Soon Ho
    Lee, Sang Woo
    Choi, Jai Hyun
    Ryu, Ho Sang
    GUT AND LIVER, 2012, 6 (02) : 262 - 269
  • [35] EFFECTS OF BEZAFIBRATE AND OF 2 HMG-COA REDUCTASE INHIBITORS ON LIPOPROTEIN-(A) LEVEL IN HYPERCHOLESTEROLEMIC PATIENTS
    BRANCHI, A
    ROVELLINI, A
    FIORENZA, AM
    SOMMARIVA, D
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 1995, 33 (06) : 345 - 350
  • [36] The Effects of Pemafibrate in Japanese Patients with Type 2 Diabetes Receiving HMG-CoA Reductase Inhibitors
    Kusunoki, Masataka
    Sakazaki, Takahiko
    Tsutsumi, Kazuhiko
    Miyata, Tetsuro
    Oshida, Yoshiharu
    ENDOCRINE METABOLIC & IMMUNE DISORDERS-DRUG TARGETS, 2021, 21 (05) : 919 - 924
  • [37] Call for a Moratorium on Routine Liver Function Testing in Patients Treated With HMG-CoA Reductase Inhibitors (Statins)
    Lehmann, David F.
    CLINICAL THERAPEUTICS, 2011, 33 (11) : 1696 - 1697
  • [38] The HMG-CoA reductase inhibitor cerivastatin lowers advanced glycation end products in patients with type 2 diabetes
    Scharnagl, H.
    Stojakovic, T.
    Winkler, K.
    Rosinger, S.
    Maerz, W.
    Boehm, B. O.
    EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2007, 115 (06) : 372 - 375
  • [39] The Pleiotropic Effects of HMG-CoA Reductase InhibitorsTheir Role in Osteoporosis and Dementia
    Alla Waldman
    Leonard Kritharides
    Drugs, 2003, 63 : 139 - 152
  • [40] HMG-CoA reductase inhibitor improves endothelial dysfunction in mineralocorticoid hypertension by inhibition of RhoA
    Hermann, M
    Ruschitzka, F
    Camici, G
    Shaw, S
    Luscher, TF
    AMERICAN JOURNAL OF HYPERTENSION, 2003, 16 (05) : 24A - 24A